Adocia SA (OTC: ADCOF) a clinical-stage biotechnology company, develops medicines using therapeutic molecules. Its product pipeline includes BioChaperone PDGF, which is in phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone Combo insulin that is in phase I/II clinical trials, as well as in pre-clinical stage for the treatment of diabetes; BioChaperone Lispro U100 that is in phase Ib clinical study for type 1 diabetes patients using an insulin pump; BioChaperone human insulin, which is in phase II clinical trials; and DriveIn, which is in preclinical stage for the treatment of oncology, as well as monoclonal antibodies for the treatment of pathologies, such as chronic inflammatory disease or oncology. Adocia has a collaborative research and license agreement with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs. The company was founded in 2005 and is headquartered in Lyon, France. For more information, visit the company’s website at www.adocia.fr.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
